Showing 3421-3430 of 5646 results for "".
- Bausch + Lomb Launches Lumify, the First OTC Redness Relieving Eye Drop With Low-Dose Brimonidinehttps://modernod.com/news/bausch-lomb-launches-lumify-the-first-otc-redness-relieving-eye-drop-with-low-dose-brimonidine/2480169/Bausch + Lomb announced the launch of Lumify (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. “With the availability of Lumify, consumers now have an in
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- ianTECH’s miLOOP Grabs Two “Best Paper of Session” Wins at the ASCRS-ASOA Annual Meetinghttps://modernod.com/news/iantechs-miloop-grabs-two-best-paper-of-session-wins-at-the-ascrs-asoa-annual-meeting/2480210/Two presentations among the several featuring ianTECH’s novel »miLOOP Device won “Best Paper in Session” awards during the 2018 meeting of the American Society of Catarac
- Omeros: Omidria Demonstrates Benefits Across Traditional and Femtosecond Laser-Assisted Cataract Surgery and in IFIS Caseshttps://modernod.com/news/omeros-omidria-demonstrates-benefits-across-traditional-and-femtosecond-laser-assisted-cataract-surgery-and-in-ifis-cases/2480226/Omeros announced that the results of four real-world clinical studies evaluating the benefits of Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual
- Dark Adaptation Testing with AdaptDx Selected for Functional Assessment in Large EU Studyhttps://modernod.com/news/dark-adaptation-testing-with-adaptdx-selected-for-functional-assessment-in-large-eu-study/2480239/MacuLogix announced that the AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study aimed at exploring novel outcome measures for f
- Imprimis to Feature its Cyclosporine/Chondroitin Sulfate and Non-Opioid MKO Melt Formulations at the Upcoming ASCRS Meetinghttps://modernod.com/news/imprimis-to-feature-its-cyclosporine-chondroitin-sulfate-and-non-opioid-mko-melt-formulations-at-the-upcoming-ascrs-meeting/2480266/Imprimis Pharmaceuticals and its ophthalmology-focused ImprimisRx division announced its participation and related physician presentations at the 2018 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the Walter E. Washington Convention Center in Washington,
- Dallas Lighthouse for the Blind to Merge With Envisionhttps://modernod.com/news/dallas-lighthouse-for-the-blind-to-merge-with-envision/2480267/Envision announced that it has acquired the Dallas Lighthouse for the Blind. Operations will continue as normal in Dallas, and the Dallas Lighthouse for the Blind name will be retained. Financial terms of the deal were not disclosed. The merger will have positive benefits both in Te
- Market Scope: Patient Demand for Better Vision Will Drive Double-Digit Growth in IOL Revenueshttps://modernod.com/news/patient-demand-for-better-vision-will-drive-double-digit-growth-in-iol-revenues/2480268/Technological innovations in premium IOLs will help drive global IOL revenues to more than $6.1 billion by 2023, according to Market Scope data.
- Tenpoint Therapeutics Appoints Stephen S. Lane, MD, as Chief Medical Officerhttps://modernod.com/news/tenpoint-therapeutics-appoints-stephen-s-lane-md-as-chief-medical-officer/2486536/Tenpoint Therapeutics announced the appointment of Stephen S. Lane, MD, as Chief Medical Officer (CMO). In this role, Dr. Lane will join the company’s executive leadership team and oversee clinical development strategy, medical affairs, and pharmacovigilance. <
- National Eye Institute Seeks Public Input for 2026–2031 Strategic Planhttps://modernod.com/news/national-eye-institute-seeks-public-input-for-20262031-strategic-plan/2486520/The National Eye Institute (NEI) has issued a Request for Information (RFI) as it begins developing its strategic plan for 2026 through 2031, inviting fe